We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazil's government has approved the exemption of 60 categories of
drugs from two national taxes, which is expected to reduce selling prices by
11% and cost the authorities some BRL125mn (US$53.34mn).
In order to improve the transparency of its regulatory decisions, prospective
European Union (EU) drug agency EMEA is to improve the framework behind its
guidelines on EU directives.
The Japan Pharmaceutical Manufacturers' Association (JPMA) has proposed
replacing the National Health Insurance system's complex price calculations
with a suggested manufacturer's reimbursement price.
Biotechnology company Gilead Sciences Inc. (GILD.O: Quote, Profile, Research) on Monday said it will pay about $341 million to acquire 65 percent of the royalty rights to its HIV drug Emtriva, which are now owned by Emory University.
Sosei Co. Ltd , a leading Japanese biopharmaceutical company with operations in Japan and the UK, announces that it has agreed terms with Arakis and its shareholders to combine its business with Arakis Limited ("Arakis"), a private UK-based biopharmaceutical company, bringing together two highly successful product discovery and development companies.
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, today announced the closing of the sale of its global biologics manufacturing business to subsidiaries of Ferring Holding SA for $80 million.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) (NASDAQ:BDSIW) announced today that it has entered into a clinical development and license agreement with Clinical Development Capital, LLC ("CDC") pursuant to which CDC will provide up to $7 million in funding for Phase III clinical trials relating
to BDSI's BEMA(TM) Fentanyl product.
Following official claims earlier this month that Nigeria is to begin manufacturing its own anti-malarials and HIV/AIDS drugs, government sources now expect a new company to reduce the country's dependence on imported vaccines.